Somatropin
Evidence: A/D — Established Human EvidenceGH Axis / Body Composition
Evidence Snapshot
What this grade covers
A for FDA-approved, finished-product-specific indications and label safety; D/E for anti-aging, bodybuilding, healthy-person fat loss, recovery, sleep, cognition, or performance use.
Regulatory Context
FDA-approved (multiple brands) for specific growth hormone deficiency and related pediatric/adult indications; anti-aging, bodybuilding, and general wellness uses are off-label and not FDA-approved.
Research Takeaway
Binds the growth hormone receptor, stimulating hepatic and peripheral IGF-1 production, which mediates most of its growth- and metabolism-related effects.
See all 11 evidence claims →Quick Summary
Somatropin is a recombinant form of human growth hormone, FDA-approved since the 1980s-2000s (multiple brands) for pediatric and adult growth hormone deficiency and several related conditions. It has one of the largest human clinical evidence bases of any compound in this catalog, but off-label wellness/anti-aging use is not supported by the same evidence and carries an open, FDA-flagged safety question about long-term mortality risk in a specific pediatric population.
Mechanism & Research Overview
Binds the growth hormone receptor, stimulating hepatic and peripheral IGF-1 production, which mediates most of its growth- and metabolism-related effects.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Binds the growth hormone receptor, stimulating hepatic and peripheral IGF-1 production, which mediates most of its growth- and metabolism-related effects.
Sources: OMNITROPE (somatropin) injection, for subcutaneous use — Prescribing Information
Supported
Somatropin (multiple brands) is FDA-approved for pediatric and adult growth hormone deficiency and several related conditions.
Sources: OMNITROPE (somatropin) injection, for subcutaneous use — Prescribing Information
Supported
A 2010 FDA safety communication reviewed a French study (SAGhE) reporting an approximately 30% increased mortality signal in a childhood-treated population and called it inconclusive due to study design weaknesses.
Supported
In a registry of 15,809 GH-treated adults with growth hormone deficiency, no dose-correlated increase in adverse events was found and cancer incidence matched the general population.
Supported
In a placebo-controlled crossover pilot study, somatropin did not improve muscle strength or function in spinal muscular atrophy.
Supported
FDA approval for somatropin is finished-product and indication specific. GENOTROPIN, NORDITROPIN, and NUTROPIN AQ each carry their own FDA-approved label, and no single brand necessarily carries every indication -- for example, Noonan syndrome appears on the NORDITROPIN label and chronic kidney disease appears on the NUTROPIN AQ label, but neither appears on every somatropin product's label. One product's indications, device, excipients, concentrations, or dosing cannot be automatically assigned to another brand.
Sources: GENOTROPIN Prescribing Information, Revised August 2024; NORDITROPIN Prescribing Information, 2025; NUTROPIN AQ Prescribing Information, Revised July 2025; FDA Drug Approvals and Databases (Somatropin)
Supported
The 2026 WADA Prohibited List prohibits growth hormone and related substances at all times in sport. A legitimate prescription does not automatically permit use in sport without the applicable therapeutic-use-exemption process; WADA status is separate from FDA approval and ordinary clinical prescribing.
Sources: 2026 World Anti-Doping Code International Standard: Prohibited List (Growth Hormone)
Supported
For approved indications, somatropin has established product-specific clinical programs supporting increased linear growth in selected pediatric conditions and replacement of endogenous growth hormone in confirmed adult growth hormone deficiency. Changes in IGF-1, lean mass, fat mass, nitrogen retention, lipolysis, or bone turnover are not by themselves proof of improved health, function, lifespan, athletic performance, or safe anti-aging benefit, and approved replacement evidence cannot be generalized to healthy adults or athletes.
Sources: GENOTROPIN Prescribing Information, Revised August 2024; NORDITROPIN Prescribing Information, 2025; NUTROPIN AQ Prescribing Information, Revised July 2025
Supported
Current FDA labels identify additional contraindications and warnings beyond those already documented on this page: pancreatitis; hypoadrenalism may be unmasked, requiring glucocorticoid-dose adjustment; hypothyroidism may appear or worsen; active proliferative or severe non-proliferative diabetic retinopathy is a contraindication depending on label; closed epiphyses is a contraindication for growth promotion; edema and fluid retention; arthralgia and carpal tunnel syndrome; and progression of pre-existing scoliosis during rapid growth. These are product-specific and depend on the exact label.
Sources: GENOTROPIN Prescribing Information, Revised August 2024; NORDITROPIN Prescribing Information, 2025; NUTROPIN AQ Prescribing Information, Revised July 2025
Supported
Evidence from FDA-approved somatropin products cannot be transferred automatically to unapproved or grey-market products labeled “HGH 191AA,” because identity, potency, purity, sterility, formulation, and manufacturing controls may differ.
Sources: NORDITROPIN Prescribing Information, 2025; OMNITROPE (somatropin) injection, for subcutaneous use — Prescribing Information; GENOTROPIN Prescribing Information, Revised August 2024
Supported
Only dosing stated in a current FDA-approved somatropin label or a named clinical study may be presented as Study/Trial Dosing context; consumer dosing recommendations are outside the evidence package.
Sources: NORDITROPIN Prescribing Information, 2025; OMNITROPE (somatropin) injection, for subcutaneous use — Prescribing Information; GENOTROPIN Prescribing Information, Revised August 2024
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Intracranial hypertension is a labeled risk per the FDA-approved prescribing information.Higher-Priority Safety Consideration
Neoplasm risk in childhood cancer survivors is a labeled risk per the FDA-approved prescribing information.Higher-Priority Safety Consideration
Sudden-death reports specific to the Prader-Willi syndrome population are a labeled risk per the FDA-approved prescribing information.Safety Consideration
Glucose intolerance and diabetes risk is a labeled concern per the FDA-approved Omnitrope prescribing information.Safety Consideration
Slipped capital femoral epiphysis is a labeled risk in pediatric patients per the FDA-approved prescribing information.Safety Consideration
Current FDA labels identify pancreatitis; hypoadrenalism that may be unmasked, requiring glucocorticoid-dose adjustment; hypothyroidism that may appear or worsen; active proliferative or severe non-proliferative diabetic retinopathy (contraindication depending on label); closed epiphyses (contraindication for growth promotion); edema and fluid retention; arthralgia and carpal tunnel syndrome; and progression of pre-existing scoliosis during rapid growth. Exact contraindications and warnings vary by product and label.Safety Consideration
FDA's 2010 safety communication reviewed a French study (SAGhE) reporting an approximately 30% increased mortality signal in a childhood-treated population and called it inconclusive due to study design weaknesses; the question was not found to be definitively resolved in this research pass.Safety Consideration
No controlled human evidence exists for anti-aging, bodybuilding, or general wellness use of somatropin — this differs materially from the approved-indication evidence base.
Research Areas Being Studied
Research areas discussed on this page reflect the GH Axis / Body Composition category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients (2022):
- Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered Subcutaneously by Needle-Free Injection (2018):
- Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study (2014):
- Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment (1998):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients | 2022 | 15,809 GH-treated adults with GHD (KIMS/Pfizer international registry) | No dose-correlated increase in adverse events; cancer incidence matched the general population.
| ||
| Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered Subcutaneously by Needle-Free Injection | 2018 | 57 healthy adults (pharmacokinetic/bioequivalence study) | Needle-free vs. standard injection device were bioequivalent on AUC, though not on Cmax.
| ||
| Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study | 2014 | 19 patients with spinal muscular atrophy | No improvement in muscle strength/function vs. placebo — a negative result, included here to avoid cherry-picking only positive studies.
| ||
| Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment | 1998 | 20 adults with childhood-onset GHD | Significant improvement in exercise capacity, sustained long-term; benefit declined after stopping treatment.
|
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| 2026 World Anti-Doping Code International Standard: Prohibited List (Growth Hormone) | 2026 | The 2026 WADA Prohibited List prohibits growth hormone and related substances at all times in sport. A legitimate prescription does not automatically permit use in sport without the applicable therapeutic-use-exemption process; WADA status is separate from FDA approval and ordinary clinical prescribing. | |||
| NORDITROPIN Prescribing Information, 2025 | 2025 | NORDITROPIN's 2025 FDA label includes pediatric growth hormone deficiency, Noonan syndrome, Turner syndrome, small for gestational age, idiopathic short stature, Prader-Willi syndrome, and adult growth hormone deficiency, along with contraindications and warnings specific to this product's formulation and device. | |||
| NUTROPIN AQ Prescribing Information, Revised July 2025 | 2025 | NUTROPIN AQ's 2025 FDA label includes pediatric growth hormone deficiency, idiopathic short stature, Turner syndrome, chronic kidney disease up to renal transplantation, and adult growth hormone deficiency, along with contraindications and warnings specific to this product's formulation and device. | |||
| A Multi-center, Randomized, Positive-control, Phase 2&3 Combined Study of Y-shape Pegylated Somatropin in Prepubertal Children With Growth Hormone Deficiency | 2024 | 434 prepubertal children with GHD | Completed trial (verified January 2024) comparing pegylated somatropin against Norditropin in prepubertal children with growth hormone deficiency. Sponsor: Xiamen Amoytop Biotech Co., Ltd. Enrollment: 434 participants. | ||
| GENOTROPIN Prescribing Information, Revised August 2024 | 2024 | GENOTROPIN's 2024 FDA label includes pediatric growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome, idiopathic short stature, and adult growth hormone deficiency, along with contraindications and warnings specific to this product's formulation and device. | |||
| OMNITROPE (somatropin) injection, for subcutaneous use — Prescribing Information | 2024 | N/A — regulatory labeling document | Full approved indications and labeled safety profile (glucose intolerance, intracranial hypertension, slipped capital femoral epiphysis, neoplasm risk in childhood cancer survivors, Prader-Willi sudden-death reports). | ||
| FDA Drug Safety Communication: Ongoing safety review of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death | 2010 | French cohort (SAGhE study) treated with GH during childhood | SAGhE study reported an approximately 30% increased mortality signal; FDA reviewed and called the study inconclusive due to design weaknesses. No definitive resolution found in this research pass. | ||
| FDA Drug Approvals and Databases (Somatropin) | FDA drug-approval databases confirm multiple somatropin brands are approved as distinct finished products, each with its own indications, formulation, device, and label -- approval is finished-product and indication specific, not a single blanket approval covering every brand or every use. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis | 2015 | Meta-analysis, 22 trials, 591 GH-treated + 562 placebo adults with GHD | Dose-dependent lean-mass/fat-mass effects; lipid benefit similar at low vs. high dose. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Somatropin is FDA-approved only for specific diagnosed conditions under medical supervision. Off-label wellness or anti-aging use is not FDA-approved and is not supported by the same evidence base as its approved indications. This is educational content, not medical advice.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for Somatropin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.